Core Viewpoint - TG Therapeutics (TGTX) has been upgraded to a Zacks Rank 2 (Buy) due to an upward trend in earnings estimates, which is a significant factor influencing stock prices [1][3]. Earnings Estimates and Stock Price Movement - The Zacks rating system emphasizes the importance of changing earnings estimates in determining near-term stock price movements, making it a valuable tool for investors [2][4]. - An increase in earnings estimates typically leads to higher fair value calculations by institutional investors, resulting in buying or selling activity that affects stock prices [4]. Company Performance and Outlook - The upgrade for TG Therapeutics indicates a positive outlook for its earnings, suggesting potential buying pressure and an increase in stock price [3][5]. - For the fiscal year ending December 2024, TG Therapeutics is expected to earn $0.09 per share, with a 24.6% increase in the Zacks Consensus Estimate over the past three months [8]. Zacks Rank System - The Zacks Rank system classifies stocks based on earnings estimate revisions, with a strong historical performance, particularly for Zacks Rank 1 stocks, which have generated an average annual return of +25% since 1988 [7]. - TG Therapeutics' upgrade to Zacks Rank 2 places it in the top 20% of Zacks-covered stocks, indicating a strong potential for market-beating returns in the near term [10].

Group 1 - TG Therapeutics, Inc. (NASDAQ: TGTX) presented at the JP Morgan Healthcare Conference, where CEO Michael Weiss discussed the company's accomplishments in 2024 and provided updates on its progress [2] - The company is part of the Growth Stock Forum, which features a model portfolio of 15-20 stocks, a top picks list of up to 10 stocks expected to perform well, and trading ideas targeting short-term and medium-term moves [2] Group 2 - The article reflects the author's opinion and does not constitute a buy or sell recommendation or investment advice [3][4]

TG Therapeutics (NASDAQ: TGTX ) is a biotech company focused on Briumvi, a treatment for Multiple Sclerosis. I will not go into great detail on the unique mechanisms of this drug, as this is not myLike millions of other investors, I got Robinhood and started trading during the pandemic. Unlike most of those investors, I carefully studied hundreds of earnings reports for clues to future performance, and I was able to identify many future winners, such as OPRX, OTRK, FUBO, and PLUG. My style of investing is i ...

TG Therapeutics (TGTX) announced preliminary net product revenues for the fourth quarter and full-year 2024 for its marketed drug, Briumvi (ublituximab-xiiy), which exceeded the company’s initial expectations.TGTX also provided its guidance for 2025 and outlined some expected milestones related to Briumvi label expansion studies and other pipeline candidates for 2025.Briumvi is approved for the treatment of certain adult patients with relapsing forms of multiple sclerosis (RMS).In the past year, shares of T ...

Company Overview - TG Therapeutics (TGTX) shares increased by 7.5% to $29.74, following a significant trading volume, despite a prior 19.6% decline over the last four weeks [1] - The company reported preliminary sales of its drug Briumvi, generating $310 million in 2024, exceeding previous expectations of $300-$305 million [2] - For 2025, management anticipates total revenues of $540 million [2] Earnings Expectations - TGTX is projected to report quarterly earnings of $0.07 per share, reflecting a year-over-year increase of 177.8% [3] - Expected revenues for the upcoming quarter are $96.61 million, representing a 119.7% increase from the same quarter last year [3] - The consensus EPS estimate for TGTX has remained unchanged over the last 30 days, indicating a potential stability in earnings expectations [4] Industry Context - TG Therapeutics operates within the Zacks Medical - Biomedical and Genetics industry, where Puma Biotech (PBYI) also competes [4] - Puma Biotech's consensus EPS estimate has increased by 50% over the past month to $0.14, although this reflects a 54.8% decrease compared to the previous year [5]

Preliminary U.S. BRIUMVI fourth quarter and full year 2024 net product revenue of $103.6 million and $310 million, respectively Full Year 2025 target total global revenue of approximately $540 million, including BRIUMVI U.S. net product revenue of approximately $525 million NEW YORK, Jan. 14, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), yesterday announced preliminary U.S. net product revenue for BRIUMVI® for the fourth quarter and full year ended December 31, 2024 (unaudited), as well as ...

Company Performance - TG Therapeutics (NASDAQ: TGTX) was rated a buy in March 2024, with the first four quarters of sales of their multiple sclerosis drug, Briumvi, making their 2024 sales guidance seem achievable [1] Industry Focus - The company operates in the biotech industry, with a focus on trading around events such as trial results and NDA/BLA approvals [1] - The industry is regulated by the FDA, which is a key factor in the company's operations and product development [1]

Presentation scheduled for Monday, January 13, 2025, at 4:30 PM PTNEW YORK, Jan. 09, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that Michael S. Weiss, the Company’s Chairman and Chief Executive Officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference. The presentation is scheduled to take place on Monday, January 13, 2025, at 4:30 PM PT. A live webcast of this presentation will be available on the Events page, located within the Investors & Media section ...

NEW YORK, Nov. 21, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced it ranked number one on the Deloitte Technology Fast 500™, a ranking of the 500 fastest-growing technology, media, telecommunications, life sciences, fintech, and energy tech companies in North America, now in its 30th year. The Company’s growth between fiscal years 2020 to 2023 was fueled by BRIUMVI® revenues, which was approved to treat adult individuals with relapsing forms of multiple sclerosis in December ...

Table of Contents Title of Class Trading Symbol(s) Exchange Name Common Stock, par value $0.001 TGTX Nasdaq Capital Market UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-32639 TG THE ...